Is Marinol (dronabinol) appropriate as an appetite stimulant for an older adult with reduced appetite?

Marinol (Dronabinol) for Appetite Stimulation in Older Adults

Marinol should NOT be routinely used as an appetite stimulant in older adults with reduced appetite, particularly those with dementia, due to very limited evidence of efficacy and significant risks of CNS adverse effects, hemodynamic instability, and falls in this vulnerable population.

Guideline-Based Recommendation

The most authoritative guidance comes from the 2024 ESPEN guidelines on nutrition in dementia, which explicitly states: "Drugs to stimulate appetite or weight gain should NOT be used in persons with dementia" 1. The 2015 ESPEN guidelines similarly recommend against the systematic use of appetite stimulants, noting that evidence is "very limited" with dronabinol tested only in small trials with weak methodology that did not achieve consistent effects on outcomes 2.

Evidence Quality and Consistency

The evidence base for dronabinol as an appetite stimulant in older adults is remarkably weak:

• Only one small RCT (n=12) in Alzheimer's patients showed increased body weight and triceps skinfold thickness after 6 weeks, despite unchanged caloric intake 2
• A retrospective chart review (n=40) of geriatric neuropsychiatric inpatients showed improvement in percentage of meals consumed, but this was uncontrolled and observational 2
• A 2009 Cochrane Review found no additional studies beyond the single small trial 2
• A 2024 updated Cochrane Review of three small trials (total n=100) found no significant effect on body weight, BMI, or energy intake in dementia patients 1

FDA-Approved Indications vs. Off-Label Use

According to the FDA label, Marinol is approved for only two specific indications 3:

1. Anorexia associated with weight loss in AIDS patients
2. Chemotherapy-induced nausea and vomiting refractory to conventional antiemetics

General appetite stimulation in older adults is NOT an FDA-approved indication. The starting dose for AIDS-related anorexia is 2.5 mg twice daily, with elderly patients recommended to start at 2.5 mg once daily to reduce CNS adverse effects 3.

Significant Safety Concerns in Older Adults

The FDA label and guidelines highlight multiple serious risks particularly relevant to older adults 3:

Central Nervous System Effects (Dose-Related)

• Dizziness, confusion, somnolence, feeling high
• Elderly patients have greater risk of psychiatric symptoms and cognitive impairment
• Problems with memory, concentration, and thinking clearly
• Worsening of pre-existing psychiatric conditions (mania, depression, schizophrenia)

Cardiovascular Risks

• Hemodynamic instability: hypotension, hypertension, syncope, tachycardia
• Elderly patients, especially those with dementia and heart problems, have increased risk of blood pressure changes and falls 3
• Increased risk of coronary heart disease, myocardial infarction, and stroke with daily use 4

Other Serious Risks

• Seizure risk - requires immediate discontinuation 3
• High potential for abuse and dependence, especially in those with substance abuse history 3
• Paradoxical nausea, vomiting, or abdominal pain 3

Alternative Evidence-Based Approaches

Rather than pharmacologic appetite stimulation, guidelines strongly recommend 2, 5:

First-Line Non-Pharmacologic Interventions

• Caregiver education on nutritional problems and feeding strategies
• Environmental modifications: dining table settings vs. tray service, social eating
• Feeding assistance: supervision, verbal prompting, encouragement, increased time with caregivers
• Energy-dense meals and between-meal snacks
• Oral nutrition supplements (strong evidence for efficacy)
• Addressing reversible causes: dental problems, poorly fitted dentures, dry mouth, medication side effects, depression

Specific Clinical Situations

If a concomitant depressive syndrome requires pharmacologic treatment, mirtazapine may be considered as it has appetite-stimulating properties and addresses the underlying depression 2. However, evidence in dementia patients is limited to one small retrospective study showing mean weight gain of 1.9-2.1 kg 1.

Clinical Decision Algorithm

For older adults with reduced appetite:

1. Identify and treat reversible causes (medication review, dental issues, depression, social isolation)
2. Implement non-pharmacologic interventions (caregiver support, environmental modifications, nutritional supplements)
3. If depression is present, consider mirtazapine for dual benefit
4. Do NOT use dronabinol for general appetite stimulation given:
   • Very low quality evidence (Grade: very low) 2
   • Lack of consistent efficacy on meaningful outcomes
   • Significant safety risks in elderly population
   • No FDA approval for this indication

Common Pitfalls to Avoid

• Assuming cannabis-based products are "natural" and therefore safe - dronabinol carries significant risks in older adults
• Using dronabinol without addressing underlying causes of poor appetite
• Failing to recognize increased fall risk from hemodynamic effects and CNS depression
• Not considering drug-drug interactions with other CNS depressants (benzodiazepines, opioids, alcohol) 6, 7
• Prescribing to patients with cardiac disease or dementia without careful risk-benefit assessment

Special Populations

Contraindications 3:

• History of hypersensitivity to dronabinol or sesame oil
• Pregnancy (avoid use - may harm fetus) 3

High-risk populations requiring extreme caution or avoidance:

• Dementia patients (explicit guideline recommendation against use) 1
• Elderly with cardiac disease
• History of psychiatric disorders
• History of substance abuse
• Seizure disorders

The evidence overwhelmingly supports prioritizing non-pharmacologic interventions and treating underlying causes rather than using dronabinol for appetite stimulation in older adults.